Tonix stock price forecast suggests cautious accumulation strategies, as institutional inflow reports show marginal increases from Q2 levels. "We are now in the realm of VIX levels that demand a policy response if stocks are to stabilize," wrote Nicholas Colas, Co-founder of DataTrek Research, in a Wednesday morning analysis. "We need to see the VIX at 80 (2008, 2020 peaks) or at least 62 (March 2020 bottom for the S&P 500) before thinking of calling a near term low for U.S. large caps," Colas added. Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements. Zembrace and Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert. Zembrace and Tosymra may cause serious side effects including: The current Tonix stock price forecast suggests potential upside if FDA approval milestones are met, with projected targets ranging between $0.50–$0.58 based on sector trend analysis.
